drugset
drugset / Trial / NCT03993379

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

NCT03993379 ↗

Phase 2 Terminated 3 enrolled CytomX Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Timeline

Start
2019-11-20
Primary completion
2020-05-21
Completion
2020-05-21

Outcome

Outcome not reported

Stopped: “Sponsor's Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject Pacmilimab Monoclonal antibody — —
Background Ipilimumab Monoclonal antibody — —

Indications

melanoma